Splenic Irradiation in Chronic Myelogenous Leukemia.
- Author:
Yoon Kyeong OH
1
;
Hyung Chul KWON
;
Sei Chul YOON
;
Yong Whee BAHK
;
Choon Choo KIM
;
Dong Jip KIM
Author Information
1. Division of Radiation Therapy, Catholic Medical College, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Splenic irrdiation;
Chronic myelogenous leukemia;
Splenomegaly
- MeSH:
Bone Marrow;
Diagnosis;
Drug Therapy;
Humans;
Karnofsky Performance Status;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Particle Accelerators;
Phosphorus;
Spleen;
Splenomegaly
- From:Journal of the Korean Society for Therapeutic Radiology
1985;3(2):137-144
- CountryRepublic of Korea
- Language:English
-
Abstract:
Radiation therapy was the treatment of choice for CML in the past, in the form of Sl or radioactive phosphorus. Its use has been replaced to a large extent by various chemotherapeutic agents. Recently Sl in CML has been used, both to relieve painful splenomegaly and to take advantage of an indirect effect of Sl on unirradiated bone marrow. We have treated 15 CML cases who had a huge spleen during chemotherapy or even after chemotherapy by 6 MV linear accelerator during the past two years at the Division of Radiation Therapy, Kang Nam St. Mar's Hospital, Catholic College. Response to Sl has been rated according to the scoring system of Roger W. Byhardt, et al. which evaluated the splenic and hematologic response as well as the response of disease-elated systems. According to this scoring system, most patients demonstrated a significant relief of splenomegaly along with improvement of hemogram. And we observed the change of Karnofsky Performance Status after Sl, and survival after a confirmative diagnosis and Sl.
